The Eli Lilly & Co. logo in the company’s digital innovation center in Singapore, Thursday, November 14, 2024.
Ore Huiying | Bloomberg | Getty images
Eli Lilly On Thursday, the income and profits of the first quarter that exceeded the estimates of their demand for weight loss and diabetes drugs have skyrocketed, but lowered its directives on the year due to the costs linked to a recent cancer treatment agreement.
The pharmaceutical giant is now expecting its adjusted profit for the year 2025, between $ 20.78 and $ 22.28 per share, down from a previous forecast of $ 22.50 to $ 24 per share. Eli Lilly said that the revision reflects an accusation of $ 1.57 billion in the first quarter, which is mainly linked to its acquisition of a certain medicine against the mouth cancer of Scorpion Therapeutics.
The company maintained its boards on sales for the year 2025 of $ 58 billion at $ 61 billion.
The treatment of successful diabetes of Eli Lilly Mounjaro exceeded expectations for the first quarter, increasing $ 3.84 billion in revenues. This represents a huge 113% compared to the same period a year ago.
The Zepbound company’s weight loss medication also beat estimates, reserving $ 2.31 billion in sales for the quarter. It is not comparable to income from the same period last year, when Zepbound had just entered the American market.
The actions of the company fell 5% in trade prior to the market.
Here is what Eli Lilly reported for the first quarter compared to what Wall Street was expecting, on the basis of a survey of LSEG analysts:
- Profit by action: $ 3.34 adjusted vs $ 3.02 expected
- Income: 12.73 billion dollars against 12.67 billion dollars expected
The company recorded turnover in the first quarter of $ 12.73 billion, up 45% compared to the same period a year ago. In the United States, sales jumped 49% to $ 8.49 billion. Eli Lilly said it was driven by a 57% increase in volume – or the number of prescriptions or units sold – for Zepbound and Mounjaro.
The pharmaceutical giant reserved a net income of $ 2.76 billion, or $ 3.06 per share, for the first quarter. This is compared to the net income of $ 2.24 billion, or at $ 2.48, a year earlier.
With the exception of the punctual elements associated with the value of intangible assets and other adjustments, Eli Lilly displayed a profit of $ 3.34 per share for the first quarter.
This story is developing. Please check the updates.
